Dr Harrison discusses how specialists can help educate PCPs on NAFLD, the importance of PCPs recognizing which individuals with NAFLD can progress to more severe liver disease, and more.
Nonalcoholic fatty liver disease is estimated to occur in 1 in 4 adults worldwide but understanding of the disease and associated complications is lacking. The American Heart Association recently released a...
It is common for patients with nonalcoholic fatty liver disease to progress to nonalcoholic steatohepatitis. Do you know which factors contribute to progression? Take our pop quiz to find out!
It is common for patients with nonalcoholic fatty liver disease to progress to nonalcoholic steatohepatitis. Do you know which factors contribute to progression? Take our pop quiz to find out!
It has been unclear whether nonalcoholic fatty liver disease is directly related to cardiovascular disease or whether this relationship is confounded by metabolic factors of NAFLD and CVD. What do you...
Do you know the percentage of patients with nonalcoholic fatty liver disease who will develop progressive disease? Test your knowledge with our pop quiz!
The gut microbiome affects the development and progression of nonalcoholic fatty liver disease. Do you know which part of the hepatic portal system connects the liver with the intestine?
In recent years, the obesity pandemic has contributed to an increase in prevalence of nonalcoholic fatty liver disease, though body mass index is only one risk factor. Do you know the estimated global...
Dr Harrison discusses how specialists can help educate PCPs on NAFLD, the importance of PCPs recognizing which individuals with NAFLD can progress to more severe liver disease, and more.
Researchers conducted a study of genomic data to clarify the relationships among nonalcoholic fatty liver disease, type 2 diabetes, and obesity. Lead author Wanqing Liu, PhD, answered our questions about...
In this video, Steven Grinspoon, MD, talks about the overall take-home messages from his session Mechanisms and Treatments for Steatosis in HIV, including what's next for research on this topic.
In this video, Steven Grinspoon, MD, talks about why treatments for steatosis in HIV are important to study, including some reasons why most studies in nonalcoholic fatty liver disease (NAFLD) do not...
In this video, Steven Grinspoon, MD, speaks about effective treatments of steatosis in patients with HIV, including whether tesamorelin could decrease liver fat in men and women living with HIV and...